GPNMB and breast carcinoma: Furthermore, the antibody-drug conjugate glembatumumab vedotin (GV), which specifically targets GPNMB, has shown initial efficacy in clinical trials for breast cancer, metastatic uveal melanoma, and osteosarcoma 18-20.